Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1999-09-10
2003-04-08
Nolan, Patrick J. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S388100, C530S413000, C435S007100, C424S139100
Reexamination Certificate
active
06545129
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to nucleic acid and amino acid sequences of a novel human selenoprotein and to the use of these sequences in the diagnosis, prevention, and treatment of cancer.
BACKGROUND OF THE INVENTION
Selenium is a trace element which is necessary for normal cellular growth and development in vivo and in vitro. In large amounts, it is a highly toxic substance; but at lower levels, it is an essential trace element in eukaryotes and a potent anticarcinogenic agent in a variety of animal models. Selenium deficiency in livestock results in degeneration of skeletal and cardiac muscle, while in humans it is associated with the development of cardiomyopathy. Dietary selenium affords protection against both the initiation and promotion of carcinogensis, and there is increasing epidemiological evidence to support its anticarcinogenic role in humans. (Medina, D. et al. (1988) Pathol. Immunopathol. Res. 7:187-199; Morris, J. G. (1984) Science 223:491-493; Batist, G. (1985) Cancer Res. 45:5900-5903; Ip, C. (1986) Adv. Exp. Med. 206:431-447; Holmberg, S. B. and Bertram, J. S. (1991) Nord Med 106:86-89).
Selenium is incorporated directly into proteins such as glutathione peroxidase, type I iodothyronine deiodinase, and selenoprotein P during translation. Incorporation of selenium into these proteins is via the selenccysteinyl-tRNA which recognizes the specific UGA codons in mRNAs to insert selenocysteine into the primary structure of selenoproteins. The biological role of selenium was established following the discovery that it is a structural component of the active center of the enzyme glutathione peroxidase.
Cellular glutathione peroxidase was the first enzyme recognized as a selenoprotein. This enzyme is composed of four apparently identical subunits, each containing one atom of selenium, and it acts as a catalyst in the reduction of hydrogen peroxide and a variety of organic hydroperoxides by glutathione. The selenium-dependent glutathione peroxidase (GSHPx) family has at least four members that protect against the deleterious effects of peroxides and hyperperoxides in tissues. These include the cellular GSHPx glutathione: H
2
O
2
oxidoreductase, the plasma GSHPx, the phospholipid hydroperoxide glutathione peroxidase, and the gastrointestinal tract associated GSHPx-GI. Several other selenoproteins have been characterized, including type I iodothyronine 5′-deiodinase which catalyzes the deiodination of L-thyroxine to the biologically active hormone 3,3′,5-triiodothyronine, and the T-cell thioredoxin reductase, a member of the thioredoxin-thioredoxin reductase antioxidant enzyme system. The selenocysteine component of these molecules is an integral part of their catalytic or active sites (Vendeland, S. C. (1995) Proc. Natl. Acad. Sci. 92:8749-8753; Zachara, B. A. (1992) J. Trace Elem. Electrolytes Health Dis. 6; 137-151; Mandel, S. J. et al. (1992) J. Clin. Endocrinol. Metab. 75:1133-1139; and Gladyshev, V. N. et al (1996) Proc. Natl. Acad. Sci. 93:6146-6151).
Levels of dietary selenium are found to regulate the enzymatic activities and the expression of the mRNAs of cellular GSHPx, phospholipid hydroperoxide glutathione peroxidase, and type I iodothyronine 5′-deiodinase. The recently isolated rat skeletal muscle selenoprotein W similarly responds to dietary selenium, although the levels of mRNA and protein do not respond in parallel. Selenoprotein W mRNA levels are relatively constant at 0.1 to 4.0 ppm selenium, but there is an 8-fold increase in the protein content which suggests additional regulation at the translational level. Like selenium-dependent GSHPx, rat skeletal muscle selenoprotein W can be isolated from muscle tissue by its binding to reduced glutathione which may imply a role in oxidation/reduction catalysis (Vendeland, S. C., supra).
Selenium-binding proteins have been implicated in cellular growth control and the protection from carcinogenesis and cancer. Antiproliferative effects of selenium have been demonstrated in brain tumor cell lines, and inhibition of DNA synthesis has been correlated with the level of selenium bound to proteins in cultured mouse mammary epithelial cells (Zhu, Z. et al. (1995) Biol. Trace Elem. Res. 49:1-7; Morrison, D. G. et al. (1988); Carcinogenesis 9:1801-1810).
The discovery of proteins related to rat skeletal muscle selenoprotein W, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions useful in diagnosis and treatment of cancer and disorders of cell growth.
SUMMARY OF THE INVENTION
The present invention features a novel human selenoprotein hereinafter designated HSEL and characterized as having similarity to rat skeletal muscle selenoprotein W.
Accordingly, the invention features a substantially purified HSEL having the amino acid sequence shown in SEQ ID NO:1.
One aspect of the invention features isolated and substantially purified polynucleotides that encode HSEL. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:2.
The invention also relates to a polynucleotide sequence comprising the complement of SEQ ID NO:2 or variants thereof. In addition, the invention features polynucleotide sequences which hybridize under stringent conditions to SEQ ID NO:2.
The invention additionally features nucleic acid sequences encoding polypeptides, oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof, and expression vectors and host cells comprising polynucleotides that encode HSEL. The present invention also features antibodies which bind specifically to HSEL, and pharmaceutical compositions comprising substantially purified HSEL. The invention also features the use of agonists and antagonists of HSEL. The invention also features a method for treating cancers by administering HSEL.
REFERENCES:
Bendayan, J. Histochemistry and Cytochemistry, 1995.*
Bost et al. Immunological Investigations, 1988.*
Medina, D. et al., “Current ideas on selenium as a chemopreventive agent”Pathol.Immunopathos.Res.,7:187-199 (1988).
Morris, J.G. et al., “Selenium deficiency in cattle associated with Heinz bodies and anemia”Science,223:491-493 (1984).
Batist, et al., “Cardiac and red blood cell glutathione peroxidase: results of a prospective randomized trial in patients on total parenteral nutrition”Cancer Res.,45:5900-5903 (1985).
Ip, C. “The chemopreventive role of selenium in carcinogenesis”Adv.Exp.Med.Biol.,206:431-447 (1986).
Holmberg, S.B. et al., “Chemopreventive of cancer. Epidermiology and basic research point to new directions”Nord.Med.,106:86-89 (1991). (Non-English article with abstract in English).
Vendeland, S.C. et al., “Rat skeletal muscle selenprotein W:cDNA clone and mRNA modulation by dietary selenium”Proc.Natl.Acad.Sci.USA,92:8749-8753 (1995).
Zachara, B.A. “Mammalian selenproteins”J.Trace Elem.Electrolytes Health Dis.,6:137-151 (1992).
Mandel, S.J. et al., “Cloning and in vitro expression of the human selenoprotein, type I iodothyronine deiodinase”J.Clin.Endocrinol.Metab.,75:1133-1139 (1992).
Gladyshev, V.N. et al., “Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene”Proc.Natl.Acad.Sci.USA,93:6146-6151 (1996).
Zhu, Z. et al., “Effect of selenium on malignant tumor cells of brain”Biol.Trace Elem.Res.,49:1-7 (1995).
Morrison, D.G. et al., “Intracellular 58-kd selenprotein levels correlate with inhibition of DNA synthesis in mammary epithelial cells”Carcinogenesis,9:1801-1810 (1988).
Georgiou, G., “Optimizing the Production of Recombinant Proteins in Microorganims”,AlChE J.,92: 8749-8753 (1995).
Vendeland, S.C. et al., (Direct Submission), GenBank Sequence Database (Accession U25264), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894, (1995) (GI 984811).
Database EST-STS, Accession No. H61256, Hillier, et al., The Washington University-Merck EST Project, Oct. 6, 1995.
Yeh et al., FASEB 9:392-396, Mar. 1995.*
Harlow et al. 1988. Antibodies
Goli Surya K.
Hillman Jennifer L.
Incyte Genomics Inc.
Incyte Genomics, Inc.
Nolan Patrick J.
LandOfFree
Human selenoprotein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human selenoprotein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human selenoprotein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3016272